Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 May;31(3):419-423.
doi: 10.1111/hae.70035. Epub 2025 Mar 23.

Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group

Marloes de Kovel  1 , Aimée-Claire van Haaster  1 , Manuel Carcao  2 , Susanna Ranta  3 , Heidi Glosli  4 , Georges E Rivard  5 , Gili Kenet  6 , Karin Kurnik  7 , Christel Van Geet  8 , Manuela Carvalho  9 , Nadine G Andersson  10   11   12 , Mutlu Kartal-Kaess  13 , Rolf Ljung  11 , H Marijke van den Berg  1 ; PedNet Study Group
Affiliations
Observational Study

Blood Group O Does Not Increase the Risk of Inhibitors in Severe Haemophilia A: Data from the PedNet Study Group

Marloes de Kovel et al. Haemophilia. 2025 May.

Abstract

Introduction: Inhibitor development against factor VIII (FVIII) is the most common complication of hemophilia A replacement therapy. One of the variables considered to influence inhibitor development is the ABO blood group. Patients with blood group O have, on average, a 30%-40% lower endogenous von Willebrand factor (VWF) concentration. It has been postulated that VWF levels influence inhibitor development. The objective of this study was to investigate the inhibitor risk in patients with severe hemophilia A comparing those with blood group O with those with non-O blood groups.

Methods: The study population consisted of children with severe hemophilia A, born between 2000 and 2020, who reached 50 FVIII exposure days in the PedNet registry. Inhibitors were considered to be clinically relevant when at least two consecutive measurements were tested positive.

Results: Routine testing of blood groups varied between centres: Out of 1172 patients with severe hemophilia A, blood group status was known in 759 patients (65.8%). The relative risk of inhibitor development for blood group O in comparison to non-O was 1.04 (95% CI: 0.7-1.7).

Conclusion: In the PedNet cohort, blood group O did not increase the risk of inhibitors in previously untreated children with severe hemophilia A.

Trial registration: PedNet Registry; clinicaltrials.gov identifier: NCT02979119.

Keywords: blood group; haemophilia; inhibitors.

PubMed Disclaimer

References

    1. J. Wight and S. Paisley, “The Epidemiology of Inhibitors in Haemophilia A: A Systematic Review,” Haemophilia 9 (2003): 418–435.
    1. T. Calvez, H. Chambost, S. Claeyssens‐Donadel, et al., “Recombinant Factor VIII Products and Inhibitor Development in Previously Untreated Boys With Severe Hemophilia A,” Blood 124 (2014): 3398–3408.
    1. S. Gouw, J. van der Brom, R. Ljung, et al., “Factor VIII Products and Inhibitor Development in Severe Hemophilia A,” New England Journal of Medicine 368 (2013): 231–239.
    1. J. Mahlangu, J. Oldenburg, M. Callaghan, et al., “Health‐Related Quality of Life and Health Status in Persons With Haemophilia A With Inhibitors: A Prospective, Multicentre, Non‐Interventional Study (NIS),” Haemophilia 25 (2019): 382–391.
    1. J. Oldenburg, H. Brackmann, and R. Schwaab, “Risk Factors for Inhibitor Development in Hemophilia A,” Haematologica 85 (2000): 7–13.

Publication types

Associated data